High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)

AIDS. 2002 Jul 26;16(11):1554-6. doi: 10.1097/00002030-200207260-00014.

Abstract

We evaluated the therapeutic outcomes of all antiretroviral-naive HIV-1-infected patients with fewer than 100 CD4 cells/microl, who received efavirenz-based highly active antiretroviral therapy (HAART). Sixty-one percent suffered AIDS-defining diseases, and after a median follow-up of 45 weeks there were three deaths and five AIDS-related conditions (two relapses, three new). Efavirenz-based HAART was found to be effective in profoundly immunosuppressed HIV-1-infected patients.

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / immunology
  • AIDS-Related Opportunistic Infections / mortality
  • AIDS-Related Opportunistic Infections / virology
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology*
  • Acquired Immunodeficiency Syndrome / mortality
  • Acquired Immunodeficiency Syndrome / virology
  • Adult
  • Alkynes
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Benzoxazines
  • CD4 Lymphocyte Count
  • Cyclopropanes
  • Female
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • Humans
  • Immunocompromised Host
  • Male
  • Middle Aged
  • Oxazines / therapeutic use*
  • Recurrence
  • Retrospective Studies

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Oxazines
  • efavirenz